Gujarat Themis Resolves Commercial Dispute in Arbitration with Optimus Drugs
Gujarat Themis Biosyn Limited has announced that it has reached an amicable resolution regarding a commercial dispute that was being handled through arbitration with Optimus Drugs Private Limited.The company had previously initiated arbitration proceedings against Optimus Drugs Private Limited over the commercial dispute. The latest update confirms that both parties have mutually settled the matter, and accordingly, the ongoing arbitration process will be disposed of based on this settlement.
Gujarat Themis Biosyn Limited confirmed that there will be no penalty paid by the Company resulting from the resolution. Furthermore, the company stated that the settlement will not result in any material financial impact.
GUJTHEM Stock Price Movement
On Monday, shares of Gujarat Themis Biosyn Limited edged higher, gaining 0.80% to settle at ₹381.95. The equity traded within a range spanning from ₹371.55 to ₹395.35, as 121,884 shares were recorded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.